Formycon Pipeline Climbs To Six As It Adds Two Biosimilars
Partner Teva In Place For Ranibizumab Launch In UK And EU
Ahead of entering the planned commercialization stage for its first biosimilar product, German biotech Formycon has revealed a series of major announcements, including that it has beefed up its pipeline with an additional two new assets. Meanwhile, it expects to soon find a commercialization partner for its proposed Stelara biosimilar.
